Cara Therapeutics Leadership

Dr. Menzaghi, one of our founders, has served as our Vice President – Research and Development since September 2004 leading our drug discovery programs and clinical operations. Dr. Menzaghi has over 20 years of drug development and management experience in biotechnology in the field of ion channels and GPCRs. Her expertise ranges from early exploratory research through clinical development, She has a successful track record in leading numerous drug discovery programs in the areas of pain, inflammation, obesity, psychiatric, cognitive and neurological disorders and guiding numerous compounds to late Phase 2 clinical trials including one compound approved by FDA in 2013 for the treatment of obesity. She has led or contributed to the filing of numerous INDs and CTAs and has led successful interdisciplinary teams spanning the entire drug development process from the validation of novel receptor targets to novel chemical entity formulated for oral, parenteral or transdermal routes of administration. From 2003-2004, she served as VP Pharmacology and Business Development at Psychogenics Inc., a preclinical central nervous system service provider. From 1099 to 2003, she was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals (NASDAQ: ARNA). Prior to that, Dr. Menzaghi established and directed a preclinical research laboratory at SIBIA Neurosciences. Her research expertise ranged from the development of small molecules to small peptides. She has extensive experience with corporate partnering with large pharmaceutical companies including Eli Lilly, Merck and J&J. Dr. Menzaghi received her Ph.D. in Neurosciences from the Louis Pasteur University, Strasbourg, France and a M.Sc. in clinical psychology from the University of Nancy. She has over 55 peer-reviewed publications and book chapters, 100 international meeting presentations and is listed as an inventor on numerous patents.

Dr. Chalmers, one of our founders, has served as our President and Chief Executive Officer since September 2004 and has served as a member of our board of directors since July 2004. Dr. Chalmers has over 19 years experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Dr. Chalmers holds a B.Sc. and Ph.D. in Pharmacology from the University of Glasgow. Dr. Chalmers’ qualifications to sit on our board of directors include his leadership, executive, managerial and business experience, historical knowledge of our company and his background and experience in the biotechnology industry, including having been a founder of a prior biotechnology company.

Dr. Lewis, one of our founders, has had extensive experience in the biopharmaceutical industry, and prior to that, about five years of experience in opioid research at the National Institutes of Health and the University of Michigan. Previously, Dr. Lewis received training in psychobiology research at the National Institute of Mental Health and at Clark University, where he received a Ph.D. in psychology, and then received postdoctoral training in psychopharmacology and neuropharmacology at the University of Cambridge. After establishing and directing a molecular neuropharmacology laboratory at DuPont, Dr. Lewis co-founded Cephalon, Inc. (Nasdaq; CEPH), serving as Director of Pharmacology and Senior Director of Scientific Affairs. Dr. Lewis later co-founded and served as Chief Scientific Advisor to Adolor Corporation (Nasdaq; ADLR), and was subsequently invited by Dr. Chalmers to co-found Arena Pharmaceuticals (Nasdaq; ARNA), where he served as a pre-IPO Director and Chief Scientific Advisor. Dr. Lewis is an inventor or co-inventor on 15 issued U.S. patents and is an author or co-author of numerous scientific papers, including over 40 publications on opioids and opioid receptors.

Joana Goncalves is a Chief Medical Officer at Cara Therapeutics Inc. She has worked as VP:Medical Affairs at CELGENE CORP. Joana works or has worked at Novartis and works or has worked as VP:Medical Strategy & Scientific Affairs at CSR. She studied at UNIVERSITY OF CAPE TOWN.

Scott Terrillion is a Chief Compliance Ofcr/Secy/Gen Cnsl at Cara Therapeutics Inc and is based in 505 Fifth Avenue, New York City, New York. He has worked as Vice President, Associate General Counsel & Head of Compliance at Mesoblast; Director of Pharmacy at Preferred Care, Rochester, NY; and Associate Attorney at Nixon Peabody LLP. Scott works or has worked as MEMBER at New York Bar and TRUSTEE at Albany College of Pharmacy and Health Sciences. He attended Albany Law School between 1987 and 1990 and Albany College of Pharmacy and Health Sciences between 1980 and 1985.

Dr. Menzaghi, one of our founders, has served as our Vice President – Research and Development since September 2004 leading our drug discovery programs and clinical operations. Dr. Menzaghi has over 20 years of drug development and management experience in biotechnology in the field of ion channels and GPCRs. Her expertise ranges from early exploratory research through clinical development, She has a successful track record in leading numerous drug discovery programs in the areas of pain, inflammation, obesity, psychiatric, cognitive and neurological disorders and guiding numerous compounds to late Phase 2 clinical trials including one compound approved by FDA in 2013 for the treatment of obesity. She has led or contributed to the filing of numerous INDs and CTAs and has led successful interdisciplinary teams spanning the entire drug development process from the validation of novel receptor targets to novel chemical entity formulated for oral, parenteral or transdermal routes of administration. From 2003-2004, she served as VP Pharmacology and Business Development at Psychogenics Inc., a preclinical central nervous system service provider. From 1099 to 2003, she was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals (NASDAQ: ARNA). Prior to that, Dr. Menzaghi established and directed a preclinical research laboratory at SIBIA Neurosciences. Her research expertise ranged from the development of small molecules to small peptides. She has extensive experience with corporate partnering with large pharmaceutical companies including Eli Lilly, Merck and J&J. Dr. Menzaghi received her Ph.D. in Neurosciences from the Louis Pasteur University, Strasbourg, France and a M.Sc. in clinical psychology from the University of Nancy. She has over 55 peer-reviewed publications and book chapters, 100 international meeting presentations and is listed as an inventor on numerous patents.

Dr. Chalmers, one of our founders, has served as our President and Chief Executive Officer since September 2004 and has served as a member of our board of directors since July 2004. Dr. Chalmers has over 19 years experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Dr. Chalmers holds a B.Sc. and Ph.D. in Pharmacology from the University of Glasgow. Dr. Chalmers’ qualifications to sit on our board of directors include his leadership, executive, managerial and business experience, historical knowledge of our company and his background and experience in the biotechnology industry, including having been a founder of a prior biotechnology company.

Dr. Lewis, one of our founders, has had extensive experience in the biopharmaceutical industry, and prior to that, about five years of experience in opioid research at the National Institutes of Health and the University of Michigan. Previously, Dr. Lewis received training in psychobiology research at the National Institute of Mental Health and at Clark University, where he received a Ph.D. in psychology, and then received postdoctoral training in psychopharmacology and neuropharmacology at the University of Cambridge. After establishing and directing a molecular neuropharmacology laboratory at DuPont, Dr. Lewis co-founded Cephalon, Inc. (Nasdaq; CEPH), serving as Director of Pharmacology and Senior Director of Scientific Affairs. Dr. Lewis later co-founded and served as Chief Scientific Advisor to Adolor Corporation (Nasdaq; ADLR), and was subsequently invited by Dr. Chalmers to co-found Arena Pharmaceuticals (Nasdaq; ARNA), where he served as a pre-IPO Director and Chief Scientific Advisor. Dr. Lewis is an inventor or co-inventor on 15 issued U.S. patents and is an author or co-author of numerous scientific papers, including over 40 publications on opioids and opioid receptors.

Dr. Menzaghi, one of our founders, has served as our Vice President – Research and Development since September 2004 leading our drug discovery programs and clinical operations. Dr. Menzaghi has over 20 years of drug development and management experience in biotechnology in the field of ion channels and GPCRs. Her expertise ranges from early exploratory research through clinical development, She has a successful track record in leading numerous drug discovery programs in the areas of pain, inflammation, obesity, psychiatric, cognitive and neurological disorders and guiding numerous compounds to late Phase 2 clinical trials including one compound approved by FDA in 2013 for the treatment of obesity. She has led or contributed to the filing of numerous INDs and CTAs and has led successful interdisciplinary teams spanning the entire drug development process from the validation of novel receptor targets to novel chemical entity formulated for oral, parenteral or transdermal routes of administration. From 2003-2004, she served as VP Pharmacology and Business Development at Psychogenics Inc., a preclinical central nervous system service provider. From 1099 to 2003, she was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals (NASDAQ: ARNA). Prior to that, Dr. Menzaghi established and directed a preclinical research laboratory at SIBIA Neurosciences. Her research expertise ranged from the development of small molecules to small peptides. She has extensive experience with corporate partnering with large pharmaceutical companies including Eli Lilly, Merck and J&J. Dr. Menzaghi received her Ph.D. in Neurosciences from the Louis Pasteur University, Strasbourg, France and a M.Sc. in clinical psychology from the University of Nancy. She has over 55 peer-reviewed publications and book chapters, 100 international meeting presentations and is listed as an inventor on numerous patents.

Dr. Chalmers, one of our founders, has served as our President and Chief Executive Officer since September 2004 and has served as a member of our board of directors since July 2004. Dr. Chalmers has over 19 years experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Dr. Chalmers holds a B.Sc. and Ph.D. in Pharmacology from the University of Glasgow. Dr. Chalmers’ qualifications to sit on our board of directors include his leadership, executive, managerial and business experience, historical knowledge of our company and his background and experience in the biotechnology industry, including having been a founder of a prior biotechnology company.